Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 06, 2015 3:23 AM ET


Company Overview of Selecta Biosciences, Inc.

Company Overview

Selecta Biosciences, Inc. is a clinical-stage biotechnology company that develops targeted immunotherapies and vaccines that regulate immune responses to prevent and treat diseases. The company provides synthetic vaccine particles (SVP) therapies that are applied in various therapeutic areas with a focus on the inhibition of immunogenicity for protein therapies, treatment of allergies, and treatment of autoimmune diseases. Its SVP therapies prevent effects of anti-drug antibodies caused by the immunogenicity of biologic drugs in patients. The company develops antigen-specific tolerogenic SVPs to prevent and suppress pro-inflammatory responses against a specific antigen for the inhibition of ...

480 Arsenal Street

Building One

Watertown, MA 02472

United States

Founded in 2007





Key Executives for Selecta Biosciences, Inc.

Chief Executive Officer, President and Director
Age: 62
Founder, Vice Chairman and Member of The Scientific Advisory Board
Age: 46
Co-Founder and Co-Chair of the Scientific Advisory Board
Co-Founder, Co-Chair of the Scientific Advisory Board and Director
Age: 67
Vice President of Finance
Compensation as of Fiscal Year 2015.

Selecta Biosciences, Inc. Key Developments

Selecta Biosciences, Inc. Appoints Earl (‘Skip’) Sands, MD, as Chief Medical Officer

Selecta Biosciences, Inc. announced the appointment of Earl (‘Skip’) Sands, MD, as Chief Medical Officer (CMO). As CMO, Dr. Sands will oversee all clinical development and regulatory activities for the company, as Selecta rapidly advances its product candidates in and toward human clinical trials for a range of diseases, including refractory gout, gene therapy, smoking cessation, human papillomavirus (HPV) associated cancers, and others. He will report directly to Selecta’s CEO Werner Cautreels, PhD, and will serve as a member of the company’s executive management team.

Selecta Biosciences Mulls IPO In Future

Selecta Biosciences, Inc. would explore an initial public offering (IPO) in future. Werner Cautreels, Chief Executive Officer of the company said “Clearly it’s something we’ll explore.”

Selecta Biosciences, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 02:00 PM

Selecta Biosciences, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 02:00 PM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Werner Cautreels, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Sunol Molecular Corporation United States
BioE Corporation United States
Tolera Therapeutics, Inc. United States
Simibio United States
University Genomics, Inc. United States

Recent Private Companies Transactions

Private Placement
August 27, 2015
Private Placement
April 10, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Selecta Biosciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at